ScoreWhy is Hansa Biopharma AB ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -7.93% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -118.62
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 5.33%, its profits have risen by 32.5%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
119.95%
EBIT Growth (5y)
-7.93%
EBIT to Interest (avg)
-118.62
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.22
Sales to Capital Employed (avg)
0.30
Tax Ratio
0.49%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-8.23
EV to EBIT
-7.79
EV to EBITDA
-7.79
EV to Capital Employed
38.79
EV to Sales
21.26
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-498.16%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
OPERATING CASH FLOW(Y)
Highest at SEK -560.17 MM
NET PROFIT(HY)
Higher at SEK -156.51 MM
RAW MATERIAL COST(Y)
Fallen by -424.68% (YoY
-4What is not working for the Company
INTEREST(9M)
At SEK 146.57 MM has Grown at 61.28%
CASH AND EQV(HY)
Lowest at SEK 604.62 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 1.11%
Here's what is working for Hansa Biopharma AB
Net Profit
Higher at SEK -156.51 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (SEK MM)
Net Profit
At SEK -156.51 MM has Grown at 62.42%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (SEK MM)
Operating Cash Flow
Highest at SEK -560.17 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (SEK MM)
Raw Material Cost
Fallen by -424.68% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Hansa Biopharma AB
Interest
At SEK 146.57 MM has Grown at 61.28%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (SEK MM)
Cash and Eqv
Lowest at SEK 604.62 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 1.11%
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
